Trial Profile

A Phase 2 Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inodiftagene-vixteplasmid (Primary)
Indications Bladder cancer
Focus Registrational; Therapeutic Use
Acronyms Codex Study
Sponsors Anchiano Therapeutics

Most Recent Events

15 Nov 2019 Results presented an Anchiano Therapeutics media release.
15 Nov 2019 Status changed from recruiting to discontinued according to an Anchiano Therapeutics media release.
23 Sep 2019 According to an Anchiano Therapeutics media release, the company is estimating that the data collection and interim analysis will be completed by the first quarter of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com